Skip to main content

Alecnib 150 mg ( Alectinib)

Alecnib 150 mg is identified on this website as a product containing alectinib, an oral targeted anticancer medicine belonging to the anaplastic lymphoma kinase (ALK) inhibitor class. Alectinib is used for certain patients with ALK-positive non-small cell lung cancer (NSCLC).

Although alectinib is a targeted cancer treatment, it can cause side effects, including serious adverse reactions that require medical attention. Patients should understand the important warnings and precautions before starting treatment and remain under medical supervision throughout therapy.

This page explains general safety considerations associated with alectinib. Product-specific instructions for Alecnib should be confirmed through its original packaging and applicable prescribing documentation.

1. Important Safety Information

Alectinib may cause adverse reactions involving different organs and body systems. Some reactions may require laboratory monitoring, treatment interruption, dosage modification, or permanent discontinuation.

Important safety concerns include:

  • Liver injury and hepatotoxicity.
  • Interstitial lung disease and pneumonitis.
  • Slow heart rate or bradycardia.
  • Muscle pain and muscle injury.
  • Hemolytic anemia.
  • Kidney impairment.
  • Severe increases in triglyceride levels.
  • Embryo-fetal toxicity.

Patients should report new or worsening symptoms to their healthcare professional. Severe or potentially life-threatening symptoms require urgent medical assessment.

2. Liver Injury and Hepatotoxicity

Alectinib may cause liver enzyme abnormalities and, in some cases, serious liver injury.

The liver plays an important role in processing medicines and maintaining normal body functions. Changes in liver function may occur during alectinib treatment, which is why regular blood testing is important.

Possible warning signs

Patients should report symptoms such as:

  • Yellowing of the skin or eyes.
  • Dark-colored urine.
  • Unusual tiredness.
  • Abdominal discomfort.
  • Loss of appetite.
  • Unexplained nausea.
  • Changes in laboratory liver function results.

Some patients may develop abnormal liver tests without noticeable symptoms.

Recommended monitoring

For the reference product Alecensa, United States prescribing information recommends monitoring ALT, AST, and total bilirubin:

  • Every two weeks during the first three months.
  • Monthly after the first three months.
  • More frequently when clinically indicated.

The healthcare professional may recommend treatment interruption or dosage modification if significant liver abnormalities develop.

Patients should not change their dose independently.

3. Interstitial Lung Disease and Pneumonitis

Alectinib may cause interstitial lung disease (ILD) or pneumonitis, conditions involving inflammation of lung tissue.

These conditions can interfere with normal breathing and may become serious.

Symptoms requiring attention

  • New or worsening cough.
  • Shortness of breath.
  • Difficulty breathing.
  • Fever.
  • Unexplained respiratory discomfort.
  • Reduced ability to perform normal physical activities because of breathing problems.

Patients should promptly report new respiratory symptoms, particularly if they develop during treatment.

If lung inflammation is suspected, the healthcare professional may arrange further investigations and decide whether treatment should be interrupted or discontinued.

Severe breathing difficulty requires immediate emergency medical attention.

4. Bradycardia and Slow Heart Rate

Alectinib may cause bradycardia, which means that the heart beats more slowly than normal.

Some patients may not experience noticeable symptoms. Others may develop symptoms that interfere with daily activities.

Possible symptoms

  • Dizziness.
  • Light-headedness.
  • Fainting.
  • Unusual weakness.
  • Tiredness.
  • Reduced exercise tolerance.
  • An unusually slow heartbeat.

Safety precautions

Patients should tell their doctor if they have a history of heart rhythm problems or take medicines that can slow the heart rate.

Healthcare professionals may monitor heart rate and blood pressure during treatment.

Patients experiencing fainting, chest discomfort, or severe dizziness should seek urgent medical assessment.

5. Muscle Pain and Muscle Injury

Alectinib may cause muscle-related adverse reactions, including myalgia and increased creatine phosphokinase (CPK).

CPK is an enzyme found in muscle tissue. Increased levels in the blood may indicate muscle injury.

Symptoms to report

  • Unexplained muscle pain.
  • Muscle tenderness.
  • Muscle weakness.
  • Difficulty performing normal movements.
  • Persistent muscle discomfort.
  • Unusual physical weakness.

For the reference Alecensa product, CPK testing is recommended every two weeks during the first month of treatment and whenever unexplained muscle symptoms occur.

If muscle injury is suspected, the healthcare professional may arrange additional tests and consider treatment modification.

6. Hemolytic Anemia

Hemolytic anemia occurs when red blood cells are destroyed faster than the body can replace them.

This condition has been reported during alectinib treatment.

Possible symptoms

  • Unusual tiredness.
  • Weakness.
  • Pale skin.
  • Dizziness.
  • Shortness of breath during activity.
  • Yellowing of the skin or eyes in some cases.

Patients should report these symptoms to their healthcare professional.

Blood tests may be necessary to investigate suspected anemia or red blood cell destruction.

7. Kidney-Related Safety Concerns

Kidney impairment has been reported during alectinib treatment, including serious cases.

The kidneys help remove waste products and maintain fluid and electrolyte balance. Changes in kidney function may affect overall health and treatment safety.

Patients should report:

  • Reduced urine output.
  • Unusual swelling.
  • Persistent nausea.
  • Unexplained weakness.
  • Other significant changes in their health.

Healthcare professionals may assess kidney function through blood and urine tests when clinically appropriate.

Patients with existing kidney problems should discuss their medical history before starting treatment.

8. Hypertriglyceridemia and Pancreatitis

Alectinib treatment may be associated with increased triglyceride levels in the blood.

Triglycerides are a type of fat circulating in the bloodstream. Very high levels can increase the risk of complications, including pancreatitis.

Possible warning signs of pancreatitis

  • Severe abdominal pain.
  • Persistent nausea.
  • Repeated vomiting.
  • Abdominal discomfort that becomes worse or does not improve.

The reference Alecensa prescribing information recommends checking triglyceride levels before treatment and periodically during therapy.

Severe or persistent abdominal pain requires prompt medical assessment.

9. Pregnancy and Embryo-Fetal Toxicity

Alectinib may cause harm to an unborn baby.

Patients who are pregnant, planning pregnancy, or could become pregnant should discuss the risks with their healthcare professional before starting treatment.

Important precautions

  • Inform the oncologist about an existing or possible pregnancy.
  • Discuss pregnancy testing when appropriate.
  • Use effective contraception according to the applicable prescribing information.
  • Inform the healthcare professional if pregnancy occurs during treatment.
  • Discuss reproductive plans before starting therapy.

For the reference Alecensa product, females of reproductive potential are advised to use effective contraception during treatment and for five weeks after the final dose. Males with female partners of reproductive potential are advised to use effective contraception during treatment and for three months after the final dose.

Patients should confirm these instructions against the applicable product information and obtain individualized advice.

10. Breastfeeding Precautions

Breastfeeding is not recommended during treatment with the reference Alecensa product under its United States prescribing information.

It is not established from this information whether alectinib or its metabolites pass into human breast milk or what effects they may have on a nursing infant.

Patients who are breastfeeding or considering breastfeeding should discuss the risks and appropriate timing with their healthcare professional.

Do not resume breastfeeding without obtaining medical advice.

11. Drug Interactions

Alectinib may interact with other medicines. These interactions may change medicine exposure or increase the possibility of adverse reactions.

Patients should provide their healthcare professional with a complete list of products they use.

This includes:

  • Prescription medicines.
  • Non-prescription medicines.
  • Vitamins and minerals.
  • Herbal preparations.
  • Dietary supplements.
  • Other anticancer treatments.

Alectinib is metabolized primarily through CYP3A4-related pathways. Medicines affecting drug metabolism and transport should be reviewed by a doctor or pharmacist.

Patients should not start, stop, or change another medicine without professional advice.

12. Precautions Before Starting Treatment

Before prescribing alectinib, the healthcare professional should review the patient’s medical history and assess whether the treatment is appropriate.

Important information to discuss includes:

Medical or personal factorWhy it matters
Liver diseaseAlectinib may cause liver injury
Kidney diseaseKidney impairment has been reported
Heart rhythm problemsTreatment may cause slow heart rate
Muscle disordersMuscle-related adverse reactions may occur
Lung diseaseRespiratory symptoms require careful assessment
PregnancyAlectinib may cause fetal harm
BreastfeedingBreastfeeding is not recommended with the reference product during treatment
Other medicinesDrug interactions and overlapping adverse reactions may occur

Patients should provide accurate medical information before treatment begins.

13. Precautions During Treatment

Patients should remain in regular contact with their oncology team throughout alectinib therapy.

Important precautions include:

  • Take the medicine according to the prescribed schedule.
  • Follow the food instructions for the specific formulation.
  • Attend recommended laboratory tests.
  • Report unusual symptoms promptly.
  • Avoid taking extra doses after a missed dose.
  • Do not replace a dose after vomiting unless specifically instructed by a healthcare professional.
  • Inform the doctor about newly prescribed medicines.
  • Do not stop treatment without medical advice.
  • Keep the medicine stored according to its packaging instructions.

Patients should maintain their scheduled follow-up appointments even when they feel well.

14. Who Should Use Extra Caution?

Certain patients may require additional clinical assessment before or during treatment.

These include:

Patients with liver impairment: Liver function should be evaluated before and during treatment.

Patients with kidney impairment: The healthcare professional should assess kidney function and consider the severity of any existing impairment.

Patients with heart conditions: Heart rate and other relevant symptoms should be reviewed.

Patients with muscle disorders: Existing muscle symptoms should be documented and evaluated.

Older adults: Treatment decisions should consider overall health, concurrent conditions, and other medicines.

Patients taking multiple medicines: A pharmacist or prescriber should review potential interactions.

These conditions do not automatically mean alectinib cannot be used. Treatment suitability must be assessed individually.

15. Signs That Require Immediate Medical Attention

Certain symptoms may indicate a serious adverse reaction.

Seek urgent medical assessment

  • Severe breathing difficulty.
  • Fainting or loss of consciousness.
  • Severe or persistent chest discomfort.
  • Serious allergic reaction, including swelling of the face or throat.
  • Severe abdominal pain with persistent vomiting.
  • Severe weakness or sudden deterioration.
  • Other potentially life-threatening symptoms.Do not wait for a routine appointment if a medical emergency is suspected.

16. What Should Patients Do If Side Effects Develop?

Patients should not ignore new or worsening symptoms during treatment.

The appropriate response depends on the type and severity of the adverse reaction.

General recommendations include:

  1. Record the symptoms and when they started.
  2. Contact the treating healthcare professional.
  3. Explain any other medicines being taken.
  4. Attend recommended examinations and laboratory tests.
  5. Follow professional instructions about treatment interruption or dosage modification.
  6. Seek urgent care if symptoms are severe.

Do not attempt to manage serious adverse reactions by independently changing the treatment dose.

17. Safety Monitoring During Alectinib Treatment

Regular monitoring helps identify possible complications and evaluate treatment tolerance.

Monitoring areaPurpose
Liver function testsDetect possible liver injury
CPK levelsInvestigate muscle injury
Heart rateIdentify bradycardia
Blood pressureSupport cardiovascular assessment
Triglyceride levelsIdentify elevated blood fats
Kidney functionAssess possible renal complications
Respiratory symptomsInvestigate possible lung inflammation
Blood testsEvaluate suspected anemia and other abnormalities
Imaging examinationsAssess cancer response when appropriate

The healthcare professional determines the appropriate monitoring schedule based on the patient and the applicable product information.

18. Can Alectinib Be Used Safely for a Long Period?

Some patients may receive alectinib for an extended period, depending on the treatment indication and response.

Long-term use requires ongoing medical supervision because adverse reactions may develop during treatment.

Patients should continue recommended monitoring and report new symptoms, even if they have previously tolerated the medicine without difficulty.

The treating oncologist will determine whether treatment should continue, be modified, or be discontinued.

19. Important Safety Advice for Caregivers

Caregivers can help patients follow their treatment plans and recognize symptoms that require medical attention.

Useful support includes:

  • Helping maintain a regular medicine schedule.
  • Keeping a record of symptoms.
  • Helping arrange laboratory tests.
  • Reviewing the medication list with the healthcare team.
  • Keeping the original packaging available.
  • Ensuring appropriate storage.
  • Helping patients seek medical attention when necessary.

Caregivers should not change the prescribed dose or make treatment decisions without professional guidance.

20. Key Safety Points to Remember

Before and during alectinib treatment, patients should remember:

  • Alectinib is a prescription targeted anticancer medicine.
  • Treatment requires confirmation of the appropriate ALK alteration.
  • Liver injury is an important safety concern.
  • New respiratory symptoms require prompt assessment.
  • Slow heart rate may occur.
  • Muscle pain and CPK elevation should be monitored.
  • Kidney impairment and hemolytic anemia are possible.
  • Pregnancy precautions are necessary.
  • Breastfeeding is not recommended during treatment with the reference product.
  • Drug interactions should be reviewed.
  • Regular medical monitoring is essential.
  • Patients should never change or stop treatment independently.

Important Medical Safety Disclaimer

This page provides general educational information about alectinib safety. It is not a substitute for the official prescribing information, professional medical advice, or an individual treatment assessment.

Alecnib is identified on this website as a product containing alectinib in a stated strength of 150 mg. Its manufacturer, formulation, regulatory status, and product-specific instructions must be verified independently.

The safety information described here includes precautions associated with the reference product Alecensa and may not represent every instruction applicable to Alecnib in every country.

Always follow the instructions of your treating oncologist and the applicable official product information. Seek urgent medical attention for serious or potentially life-threatening symptoms.